Resultados da pesquisa - (((( ((so open) OR (do open)) ) or ( _ opens ))) or ( esmo open ))*

Pesquisas alternativas:
so open » ao open (Expandir a Pesquisa), o open (Expandir a Pesquisa), caso open (Expandir a Pesquisa)
do open » oto open (Expandir a Pesquisa), two open (Expandir a Pesquisa)
_ opens » _ open (Expandir a Pesquisa), _ operons (Expandir a Pesquisa), _ opened (Expandir a Pesquisa)
esmo » esto (Expandir a Pesquisa), eso (Expandir a Pesquisa), ecmo (Expandir a Pesquisa)

1

AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype

AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BT...

Por Yoo, Changhoon, Oh, Do-Youn, Choi, Hye Jin, Kudo, Masatoshi, Ueno, Makoto, Kondo, Shunsuke, Chen, Li-Tzong, Osada, Motonobu, Helwig, Christoph, Dussault, Isabelle, Ikeda, Masafumi
Publicado no Hepatobiliary Surg Nutr (2019)

“... of the ongoing phase 1, open-label trial NCT02699515. The primary objective is safety/tolerability; secondary...”
Obter o texto integral
Obter o texto integral

Artigo

2

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL stud...

Por Bennouna, Jaafar, Barlesi, Fabrice, Do, Pascal, Dumont, Patrick, Cadranel, Jacques, Debieuvre, Didier, Hilgers, Werner, Molinier, Olivier, Quoix, Elisabeth, Raimbourg, Judith, Langlais, Alexandra, Morin, Franck, Souquet, Pierre-Jean
Publicado no ESMO Open (2018)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

3

Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey

Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey

Por Li, Chi Kong, Dalvi, Rashmi, Yonemori, Kan, Ariffin, Hany, Lyu, Chuhl Joo, Farid, Mohamad, Gonzales-Santos, Julieta Rita N, Zhou, Qing, Bielack, Stefan, Brugieres, Laurence, Blondeel, Anne, Essiaf, Samira, Peccatori, Fedro Alessandro, Jezdic, Svetlana, Stark, Daniel P, Douillard, Jean-Yves, Saloustros, Emmanouil, Mountzios, Giannis
Publicado no ESMO Open (2019)

“... their patients on a healthy lifestyle. Even so, 46% did not ask about smokeless tobacco habits and only half...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

4

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?

Por Poggio, Francesca, Lambertini, Matteo, de Azambuja, Evandro
Publicado no ESMO Open (2018)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

5

Where do they come from? A call for complete transparency regarding the origin of human tissues in research

Where do they come from? A call for complete transparency regarding the origin of human tissues in research

Por Hildebrandt, Sabine, Seidelman, William E
Publicado no ESMO Open (2017)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

6

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?

Por Schuller, Yvonne, Biegstraaten, Marieke, Hollak, Carla E. M., Klümpen, Heinz-Josef, Gispen-de Wied, Christine C., Stoyanova-Beninska, Violeta
Publicado no Orphanet J Rare Dis (2018)

“... Society for Medical Oncology - Magnitude of Clinical Benefit Scale (ESMO-MCBS). To estimate real-world...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

7

Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund

Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund

Por Aggarwal, A., Fojo, T., Chamberlain, C., Davis, C., Sullivan, R.
Publicado no Ann Oncol (2017)

“... scales, only 23 (48%) and 9 (18%) of the 47 drug indications met ASCO and ESMO criteria, respectively...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

8

Cancer and the arts: how often do doctors only see what they want to see? Or: the case of an ‘epidemic of breast cancer among famous artists’

Cancer and the arts: how often do doctors only see what they want to see? Or: the case of an ‘epidemic of breast cancer among famous artists’

Por Wagner, Wolfgang
Publicado no ESMO Open (2017)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

9

Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis

Do patients with reduced or excellent performance status derive the same clinical benefit from...

Por Cheng, Sierra, Qureshi, Mahin, Pullenayegum, Eleanor, Haynes, Adam, Chan, Kelvin KW
Publicado no ESMO Open (2017)

Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

10

Educational video: the role of PD-L1 in the local tumour microenvironment

Educational video: the role of PD-L1 in the local tumour microenvironment

Por Preusser, Matthias, Berghoff, Anna S, Thallinger, Christiane, Zielinski, Christoph C
Publicado no ESMO Open (2017)

“.... Therapeutic monoclonal antibodies that bind to PD-1 or PD-L1, so called immune checkpoint inhibitors, prevent...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

11

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations

Por Jiang, Di Maria, Chan, Kelvin K. W., Jang, Raymond W., Booth, Christopher, Liu, Geoffrey, Amir, Eitan, Mason, Robert, Everest, Louis, Elimova, Elena
Publicado no Cancer Med (2019)

“... FDA–approved gastrointestinal cancer drugs do not meet the ESMO threshold of substantial clinical...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

12

Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach

Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach

Por Lin, Frank P. Y., Pokorny, Adrian, Teng, Christina, Dear, Rachel, Epstein, Richard J.
Publicado no BMC Cancer (2016)

“... stratified ten-fold cross-validations. The predictions so derived were duly compared with those based...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

13

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer

Por Granier, Clemence, De Guillebon, Eleonore, Blanc, Charlotte, Roussel, Helene, Badoual, Cecile, Colin, Elia, Saldmann, Antonin, Gey, Alain, Oudard, Stephane, Tartour, Eric
Publicado no ESMO Open (2017)

“... and, since 2011, have opened a new area of antitumour immunotherapy. Many antibodies targeting other...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

14

From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26–30th September 2014

From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26–30th September 2014

Por Curigliano, Giuseppe
Publicado em 2014

“... Society of Medical Oncology (ESMO) Congress. The meeting assembled 19,859 participants from nearly 134...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

15

Cancer research in the era of immunogenomics

Cancer research in the era of immunogenomics

Por Wolf, Yochai, Samuels, Yardena
Publicado no ESMO Open (2018)

“... in a wide range of tumour types. Despite these advances, many tumours do not respond...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

16

TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib

TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib

Por Poudyal, Bishesh Sharma, Tuladhar, Sampurna, Gyawali, Bishal
Publicado no ESMO Open (2016)

“..., TKI continuation in the patient with CML is important. So we treated him with prednisone, but his...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

17

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)

Por Piechutta, Manuel, Berghoff, Anna Sophie
Publicado no ESMO Open (2019)

“... storm, hepatoxicity, thromboembolic events and were so far reported to be clinically manageable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

18

Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature

Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature

Por Kastrisiou, Myrto, Kostadima, Fereniki-Lida, Kefas, Aristides, Zarkavelis, George, Kapodistrias, Nikos, Ntouvelis, Evangelos, Petrakis, Dimitrios, Papadaki, Alexandra, Vassou, Amalia, Pentheroudakis, George
Publicado no ESMO Open (2017)

“... such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

19

Choosing wisely in oncology: necessity and obstacles

Choosing wisely in oncology: necessity and obstacles

Por Saletti, Piercarlo, Sanna, Piero, Gabutti, Luca, Ghielmini, Michele
Publicado no ESMO Open (2018)

“... in the oncological setting and focus on the strategies which could allow CW to evolve in the cancer field, so...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

20

How we treat glioblastoma

How we treat glioblastoma

Por Weller, Michael, Le Rhun, Emilie, Preusser, Matthias, Tonn, Jörg-Christian, Roth, Patrick
Publicado no ESMO Open (2019)

“.... Temozolomide given during radiotherapy followed by six cycles of maintenance chemotherapy was the first and so...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo